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Objective: Genetic variants robustly associated with coronary artery disease were reported in the vicinity
of the interleukin (IL)-5 locus, and animal studies suggested a protective role for IL-5 in atherosclerosis.
Therefore, we set this work to explore IL-5 as a plasma biomarker for early subclinical atherosclerosis, as
determined by measures of baseline severity and change over time of carotid intima-media thickness
(cIMT).
Methods: We used biobank and databases of IMPROVE, a large European prospective cohort study of
high-risk individuals (n ¼ 3534) free of clinically overt cardiovascular disease at enrollment, in whom
composite and segment-specific measures of cIMT were recorded at baseline and after 15 and 30 months.
IL-5 was measured with an immunoassay in plasma samples taken at baseline.
Results: IL-5 levels were lower in women than in men, lower in the South than in North of Europe, and
showed positive correlations with most established risk factors. IL-5 showed significant inverse re-
lationships with cIMT change over time in the common carotid segment in women, but no significant
relationships to baseline cIMT in either men or women.
Conclusions: Our results suggest that IL-5 may be part of protective mechanisms operating in early
atherosclerosis, at least in women. However, the relationships are weak and whereas IL-5 has been
proposed as a potential molecular target to treat allergies, it is difficult to envisage such a scenario in
coronary artery disease.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).oronary artery disease; IL, interleukin; cIMT, carotid intima-media thickness; SBP, systolic blood pressure; DBP, diastolic
gh-density lipoprotein; CRP, C-reactive protein; BMI, body-mass index; IMTmean, mean IMT of the whole carotid tree;
mean-max, average of maximum IMT values of the whole carotid tree; CC, common carotid artery; ICA, internal carotid
a Media Thickness and IMT-PROgression as Predictors of Vascular Events in a High-Risk European Population.
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at latitudes 43, 45, 48, 53, 59 and 62, respectively. BetweenInflammation plays an important role in atherosclerosis and
clinical cardiovascular disease (CVD) [1e3]. Epidemiological studies
have shown that patients with chronic inflammatory diseases, such
as rheumatoid arthritis, lupus erythematosus and psoriasis, run a
significantly greater risk of contracting coronary artery disease
(CAD) than the general population, a fact that is not fully explained
by presence of traditional cardiovascular risk factors [3,4]. Instead,
it appears that inflammation and an increased proportion of un-
stable plaques contribute substantially to the increased cardiovas-
cular mortality in rheumatoid arthritis [4]. In addition, the absence
of an increase in occurrence of clinical CAD prior to the onset of
rheumatoid arthritis [5], and the reduced risk of CAD achieved by
blocking tumor necrosis factor early in the course of rheumatoid
arthritis [6], suggest that CAD develops after the onset of rheu-
matoid arthritis. Genetic studies have also supported the hypoth-
esis that pro-inflammatory pathways play a causal role in CAD [7].
Interleukins (ILs) in particular can be considered as strong candi-
dates because they are known to influence the cardiovascular sys-
tem in either a harmful, pro-inflammatory way (IL-1, IL-2, IL-6, IL-7,
IL-8, IL-15, IL-17, and IL-18) or in a protective, anti-inflammatory
way (IL-4, IL-10, IL-11, IL-12, and IL-13) [8]. Accordingly, meta-
analyses of genetic studies have provided strong evidence for IL-6
and the IL-6 receptor in CAD [9,10].
In 2011, genetic variants in the vicinity of the IL-5 locus were
found to be robustly associated with CAD in a large caseecontrol
study including a total of 32,717 cases and 75,465 control subjects
[11]. IL-5 was originally defined as a “T-cell-replacing factor” that
drives activated B cells for terminal differentiation into antibody-
secreting plasma cells in mice [12]. In humans, IL-5 is best char-
acterized as a major maturation and differentiation factor for eo-
sinophils [13]. Because of the importance of eosinophils for allergy
and other associated disorders, IL-5 has been proposed as a po-
tential molecular target for the treatment of these diseases, with a
couple of IL-5 antagonist therapies currently under development
[13,14]. Prior to the recent gene-centric study in CAD [11], the role
of IL-5 in CVD had been barely touched upon, with one publication
linking plasma IL-5 levels inversely to subclinical atherosclerosis
[15] and two studies implicating raised IL-5 levels in unstable
angina and myocardial infarction [16] and risk of recurrent CAD
events [17].
Against this background, we examined the role of IL-5 as a
plasma biomarker for early, subclinical carotid atherosclerosis, as
determined by measures of baseline severity and change over time
in carotid intima-media thickness (cIMT), in a large prospective
cohort study of high-risk individuals who were free of clinically
overt CVD at enrollment [18].2. Materials and methods
2.1. Study population
The present study was performed using the biobank and da-
tabases of a multicentre, European, longitudinal cohort study
(acronym: IMPROVE (Carotid Intima Media Thickness (cIMT) and
IMT-PROgression as Predictors of Vascular Events in a High-Risk
European Population) [18]). In brief, inclusion criteria were age
from 55 to 79 years, presence of at least three cardiovascular risk
factors and absence of symptoms of CVD, as well as of conditions
that might limit longevity or cIMT visualization. Participants
were recruited in seven centers in five European countries: Italy
(centers in Perugia and Milan), France (Paris), the Netherlands
(Groningen), Sweden (Stockholm) and Finland (two centers inMarch 2004 and April 2005, 3711 participants were enrolled, of
whom 3534 (1701 men and 1833 women) were included in the
present report. Participants were excluded because of inaccuracy
of data at recruitment, technical difficulty to acquire cIMT or
incomplete follow-up, as detailed [19]. Ethics committee ap-
provals for the study were obtained in each of the 7 recruiting
centres and written informed consents were obtained from all
participants.
Baseline characteristics of the entire IMPROVE cohort and
methods for determination of established cardiovascular risk fac-
tors have been published [18].
2.2. Quantification of IL-5 in plasma
The concentration of IL-5 was measured in duplicate in EDTA-
plasma samples by a sandwich immunoassay with electro-
chemiluminescense detection using the ultra-sensitive kit for hu-
man IL-5 assay from MesoScale Discovery, Gaithersburg, MD, USA
(Catalog #: K1151AJC-4, Lot: K0022251). All samples were incu-
bated overnight at 4 C with the antibody on the wells of plates, on
a shaker at 600 rpm. Otherwise the protocol followed the manu-
facturer's instructions. The mean intra-assay coefficient of variation
(CV) for all samples was 8%, and the inter-assay CV for the control
plasma was 13% (n ¼ 94 plates).
2.3. Carotid ultrasonography
Details of the protocol and validation of the carotid ultrasound
measurements have been published [18]. In the present report, the
following cIMT variables were studied in relation to IL-5: the mean
and maximum IMT of the whole carotid tree (IMTmean and
IMTmax), and the average of maximum IMT values of the whole
carotid tree (IMTmean-max); the mean and maximum IMT of the
common carotid arteries (CC-IMTmean and CC-IMTmax), excluding
the first centimetre closest to the bifurcation; the mean and
maximum IMT of the internal carotid artery (ICA-IMTmean and
ICA-IMTmax); and the mean and maximum IMT of the bifurcations
(Bif-IMTmean and Bif-IMTmax). Participants underwent cIMT
measurements at 3 time-points: baseline and after 15 and 30
months. Changes in cIMT over 30 months, expressed in mm/year,
were calculated by linear regression of IMT versus time using data
from the 3 time-points.
2.4. Variable definitions
Hypertension was defined as a diagnosis of hypertension and/
or treatment with antihypertensive drugs. Diabetes was defined
as a diagnosis of diabetes and/or treatment with insulin or other
hypoglycemic drug, and/or fasting glucose 7 mmol/L at the
baseline examination. Smoking habits, identified from a struc-
tured questionnaire performed at baseline, included variables
reflecting current smoking status, duration/cessation of smoking
and the average number of cigarettes being consumed. As a
measure of cumulative smoking, a 'pack-years' variable was
calculated by multiplying the average number of cigarettes
smoked per day by the number of years of smoking divided by 20.
The 'pack-years' was used as a 5-level categorical variable where
first group included never-smoker status and four other included
quartiles of 'pack-years'. Results were presented as percent of
population in smoking groups 0/1/2/3/4: 0: non-smokers; 1 to 4
correspond respectively to 0e7.99; 8e17.99; 18e29.99; 30-250
pack-years.
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Variables are reported as number of subjects in group (propor-
tion) or median (interquartile range). Variables with skewed dis-
tribution were logarithmically transformed before they were used
in analysis.
Differences in IL-5 levels across recruitment centers were
analyzed by the JonckheereeTerpstra test for ordered alternatives
to assess trends across centers defined by their latitude (the two
Finnish centers were analyzed together). Comparisons of IL-5 and
other variables between men and women were calculated by
ManneWhitney U test. Associations between IL-5 levels and car-
diovascular risk factors were assessed by calculation of Spearman
rank correlation coefficients. Conventional risk factors and risk
factors which were significantly correlated with IL-5 were used in
the selection of covariates for the regression models.
Multivariable analysis of factors associated with IL-5 levels was
performed bymultiple linear regression. Multiple robust regression
was used to assess associations between IL-5 levels and cIMT
measurements [20]. Age was always forced into the models, which
also included latitude, and a range of relevant clinical and
biochemical variables. Because the cIMT variables were strongly
correlated with each other correction for multiple testing was not
performed.Table 1
Characteristics of the participants.
All subjects Males Females P-
valuea
n 3534 1701 1833
Age, years 64.4 (59.6e67.2) 64.3 (59.3e67.1) 64.6 (60.0
e67.3)
0.055
BMI, kg/m2 26.8 (24.3e29.5) 27.1 (25.0e29.3) 26.4 (23.6
e29.7)
<0.001
Waist/hip ratio 0.92 (0.86e0.97) 0.96 (0.93e1.01) 0.87 (0.82
e0.91)
<0.001
SBP, mmHg 140 (130e153) 141 (130e154) 140 (130
e152)
0.148
DBP, mmHg 81 (75e88) 83 (77e90) 80 (75e88) <0.001
Hypertension 2436 (68.9) 1151 (67.7) 1285 (70.1) 0.118
LDL-cholesterol,
mmol/L
3.50 (2.82e4.22) 3.37 (2.75e4.03) 3.64 (2.93
e4.38)
<0.001
HDL-cholesterol,
mmol/L
1.20 (1.01e1.46) 1.10 (0.93e1.30) 1.32 (1.11
e1.60)
<0.001
Triglycerides,
mmol/L
1.31 (0.94e1.90) 1.38 (0.97e2.03) 1.26 (0.91
e1.78)
<0.001
Glucose, mmol/L 5.5 (5e6.3) 5.7 (5.2e6.6) 5.3 (4.8e6.0) <0.001
Diabetes mellitus 929 (26.3) 533 (31.9) 396 (21.9) <0.001
CRP, mg/L 1.86 (0.77e3.58) 1.64 (0.67e3.24) 2.09 (0.92
e3.95)
<0.001
Current smokers 512 (14.9) 274 (16.6) 238 (13.4) 0.009
Pack-years, % 49.1/12.6/12.5/
12.6/13.1
32.2/15.1/16.6/
15.7/20.4
64.3/10.4/8.8/
9.8/6.6
<0.001
Creatinine, mmol/
L
79.1 (68.5e90.7) 88.6 (79.7e98.6) 70.6 (63.0
e79.3)
<0.001
Vitamin D, nmol/L 48 (34e64) 50 (37e65) 47 (30.5e61) <0.001
Adiponectin, mg/
mL
10.6 (6.2e17.2) 8.1 (4.8e12.1) 14.0 (8.6
e21.9)
<0.001
IL-5, pg/mL 0.43 (0.27e0.71) 0.48 (0.30e0.77) 0.39 (0.25
e0.64)
<0.001
Values are expressed as median (interquartile range) or number of subjects in group
(%).
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive pro-
tein; IL-5, Interleukin-5. Hypertension: diagnosis of hypertension and/or treatment
with antihypertensive drugs; Diabetes: diagnosis of diabetes and/or treatment with
insulin or other hypoglycemic drug, and/or fasting glucose 7 mmol/L at the
baseline examination.
a P-values for comparisons between men and women were calculated by Man-
neWhitney U test.A two-sided p-value <0.05 was considered significant for all
analyses. STATA 11.1 (StataCorp LP) and SAS 9.2 for Windows were
used for the statistical analyses.
3. Results
3.1. Characteristics of the participants
Baseline anthropometric, biochemical and environmental
characteristics showed significant differences between male and
female participants of the present substudy for the majority of
variables (Table 1). In general, the levels of the risk factors analyzed
showed a more beneficial profile in women, with exception of LDL-
cholesterol and Vitamin D, which were better in man.
3.2. Plasma IL-5 concentration according to latitude and sex
The median plasma IL-5 concentration in all IMPROVE partici-
pants was 0.43 (0.27e0.71) pg/mL [median (interquartile range)], a
figure that differed significantly across centers, defined by their
latitudes, [0.38 (0.23e0.66), 0.32 (0.20e0.55), 0.41 (0.25e0.66),
0.45 (0.29e0.71), 0.49 (0.29e0.78) and 0.50 (0.33e0.77) pg/mL at
latitudes 43, 45, 48, 53, 59 and 62, respectively], with a trend for
lower levels in the South of Europe (p < 0.001).
Plasma IL-5 concentrations also differed by sex, with lower
values in women [0.39 (0.25e0.64) versus 0.48 (0.30e0.77) pg/mL
in men, p < 0.001, Table 1].
3.3. Relationships of IL-5 to risk factors for cardiovascular disease
Table 2 shows the relationships of IL-5 to cardiovascular risk
factors. In both men and women, significant positive associations
were found between IL-5 concentration and latitude, age, body
mass index (BMI), SBP, hypertension, glucose, diabetes, CRP,
creatinine and vitamin D, and a significant negative associationTable 2
Relationships of plasma IL-5 concentration to risk factors for cardiovascular disease
in male and female participants.
Males Females
Rho P-value Rho P-value
Latitude 0.146 <0.001 0.163 <0.001
Age, years 0.086 <0.001 0.063 0.007
BMI, kg/m2 0.048 0.048 0.090 <0.001
Waist/hip ratio 0.039 0.105 0.023 0.318
SBP, mmHg 0.059 0.016 0.085 <0.001
DBP, mmHg 0.014 0.559 0.023 0.321
Hypertension 0.088 <0.001 0.095 <0.001
LDL-cholesterol, mmol/L 0.019 0.450 0.112 <0.001
HDL-cholesterol, mmol/L 0.041 0.092 0.021 0.380
Triglycerides,mmol/L 0.017 0.481 0.022 0.357
Glucose, mmol/L 0.067 0.006 0.057 0.014
Diabetes 0.065 0.008 0.073 0.002
Current smokers 0.007 0.763 0.022 0.353
Pack-years, % 0.013 0.602 0.009 0.717
CRP, mg/L 0.053 0.030 0.081 0.001
Creatinine, mmol/L 0.080 0.001 0.093 <0.001
Vitamin D, nmol/L 0.057 0.020 0.053 0.026
Adiponectin, mg/mL 0.058 0.017 0.115 <0.001
Statin use 0.037 0.130 0.022 0.355
Values are Spearman rank correlation coefficients.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive pro-
tein. Hypertension: diagnosis of hypertension and/or treatment with antihyper-
tensive drugs; Diabetes: diagnosis of diabetes and/or treatment with insulin or
other hypoglycemic drug, and/or fasting glucose 7 mmol/L at the baseline
examination.
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ever rather weak; latitude was the strongest associated factor. The
only sex-specific difference was a negative association of IL-5 with
LDL-cholesterol, observed in women.
Multivariable analyses showed that independently related var-
iables accounted for a total of 3.9% and 3.8% of the variability in
plasma IL-5 concentration in men and women, respectively. The
contributing factors in men included age, latitude, SBP, hyperten-
sion, HDL-cholesterol, CRP, creatinine and diabetes, whereas the
model in women included age, latitude, LDL-cholesterol, CRP,
creatinine and adiponectin.
3.4. Relationships of plasma IL-5 levels to measures of baseline
cIMT and change over time in cIMT
At baseline, after adjustment by age, the plasma IL-5 concen-
tration correlated significantly and positively with all compositeTable 3
Relationships of plasma IL-5 concentration to baseline and progression measures of
carotid artery intima-media thickness.
Baseline measures Progression measures
b ± 2 SE p-value b ± 2 SE p-value
A. Adjustment for age
MALES N ¼ 1701 N ¼ 1663*
IMTmean 0.0083 ± 0.0056 0.003 0.0003 ± 0.0020 0.769
IMTmax 0.0112 ± 0.0102 0.028 0.0038 ± 0.0084 0.369
IMTmean-max 0.0087 ± 0.0058 0.003 0.0006 ± 0.0032 0.707
CC-IMTmean 0.0024 ± 0.0044 0.283 0.0001 ± 0.0016 0.940
CC-IMTmax 0.0054 ± 0.0068 0.107 0.0012 ± 0.0040 0.540
ICA-IMTmean 0.0101 ± 0.0090 0.025 0.0011 ± 0.0032 0.522
ICA-IMTmax 0.0129 ± 0.0122 0.033 0.0041 ± 0.0068 0.233
Bif-IMTmean 0.0072 ± 0.0088 0.102 0.0020 ± 0.0040 0.326
Bif-IMTmax 0.0081 ± 0.0106 0.128 0.0023 ± 0.0078 0.560
FEMALES N ¼ 1833 N ¼ 1772*
IMTmean 0.0023 ± 0.0046 0.314 0.0002 ± 0.0016 0.802
IMTmax 0.0041 ± 0.0094 0.379 0.0006 ± 0.0066 0.854
IMTmean-max 0.0024 ± 0.0048 0.327 0.0001 ± 0.0024 0.951
CC-IMTmean 0.0010 ± 0.0034 0.550 0.0017 ± 0.0012 0.007
CC-IMTmax 0.0003 ± 0.0044 0.893 0.0024 ± 0.0028 0.085
ICA-IMTmean 0.0042 ± 0.0070 0.226 0.00004 ± 0.0022 0.966
ICA-IMTmax 0.0075 ± 0.0098 0.127 0.0027 ± 0.0046 0.244
Bif-IMTmean 0.0006 ± 0.0078 0.870 0.0009 ± 0.0034 0.585
Bif-IMTmax 0.0015 ± 0.0094 0.746 0.0012 ± 0.0066 0.707
B. Adjustment for age and latitude
MALES N ¼ 1701 N ¼ 1663*
IMTmean 0.0046 ± 0.0054 0.089 0.0009 ± 0.0020 0.399
IMTmax 0.0057 ± 0.0102 0.259 0.0027 ± 0.0086 0.535
IMTmean-max 0.0044 ± 0.0058 0.123 0.0001 ± 0.0032 0.938
CC-IMTmean 0.0004 ± 0.0044 0.872 0.0003 ± 0.0016 0.669
CC-IMTmax 0.0026 ± 0.0068 0.437 0.0016 ± 0.0040 0.429
ICA-IMTmean 0.0055 ± 0.0090 0.214 0.0002 ± 0.0034 0.901
ICA-IMTmax 0.0074 ± 0.0120 0.217 0.0033 ± 0.0068 0.342
Bif-IMTmean 0.0021 ± 0.0086 0.634 0.0030 ± 0.0042 0.150
Bif-IMTmax 0.0017 ± 0.0104 0.748 0.0009 ± 0.0080 0.822
FEMALES N ¼ 1833 N ¼ 1772*
IMTmean 0.0007 ± 0.0044 0.749 0.0003 ± 0.0016 0.726
IMTmax 0.0009 ± 0.0092 0.839 0.0007 ± 0.0066 0.840
IMTmean-max 0.0012 ± 0.0048 0.605 0.0001 ± 0.0026 0.951
CC-IMTmean 0.0009 ± 0.0032 0.594 0.0019 ± 0.0012 0.003
CC-IMTmax 0.0015 ± 0.0042 0.469 0.0025 ± 0.0028 0.073
ICA-IMTmean 0.0003 ± 0.0068 0.910 0.0001 ± 0.0022 0.900
ICA-IMTmax 0.0025 ± 0.0098 0.611 0.0024 ± 0.0048 0.315
Bif-IMTmean 0.0033 ± 0.0076 0.387 0.0011 ± 0.0034 0.528
Bif-IMTmax 0.0033 ± 0.0996 0.488 0.0013 ± 0.0066 0.707
Values are b, regression coefficient and SE, standard error. Different measurements
of baseline IMT were log-transformed to achieve normal distribution. *Number of
participants with complete IMT data at all time points (baseline, 15 and 30 months).
IMT, intima-media thickness; IMTmean, mean IMT of the whole carotid tree;
IMTmax, maximum IMT of the whole carotid tree; IMTmean-max, average of
maximum IMT values of the whole carotid tree; CC, common carotid artery; ICA,
internal carotid artery; Bif, bifurcation (bulb).(IMTmean, IMTmax, IMTmean-max) and with segment-specific
(ICA-IMTmean and ICA-IMTmax) IMT measurements in men but
not in women (Table 3A). Because of these preliminary sex-specific
relationships of IL-5 to cIMT, subsequent multivariable analyses
were then performed separately in men and women. Successive
adjustments weremade, first by latitude followed by risk factors for
cardiovascular disease. Adjustment by latitude blunted all signifi-
cant associations between IL-5 and baseline cIMT variables in men
(Table 3B). Further adjustments (by waist/hip ratio, triglycerides,
LDL-cholesterol, HDL-cholesterol, hypertension, diabetes, smoking,
CRP, statin use, heart rate, and mean arterial pressure) did not
change these results (not shown).
Similar analysis for the relationships of plasma IL-5 concentra-
tion to change over time in values of cIMT produced statistically
significant inverse relationships for CC-IMTmean (with a trend for
CC-IMTmax) in women after adjustment for age (Table 3A) and age
plus latitude (Table 3B). Further adjustments did not materially
change these results. In the final model, which included adjust-
ments for age, latitude, waist/hip ratio, triglycerides, LDL-
cholesterol, HDL-cholesterol, hypertension, diabetes, smoking,
CRP, statin use, heart rate and mean arterial pressure, values for
[b ± 2 SE] and p were [0.0020 ± 0.0012] and 0.002, respectively,
for the relation between IL-5 and changes in CC-IMTmean in
women. In men no statistically significant relationship was
observed between plasma IL-5 and change over time in any cIMT
measure. Inclusion of an interaction term in the multivariable
analysis showed a trend for sex differences in the IL-5 effect on CC-
IMTmean progression (p ¼ 0.097) but not on CC-IMTmax
(p ¼ 0.512).
3.5. Relationships of plasma IL-5 levels to blood eosinophil count
In men andwomen, from the five centers inwhich the datawere
available (no eosinophil count was recorded in either Finish cen-
ters), IL-5 was consistently, positively and strongly correlated to the
eosinophil counts (n ¼ 2494, r ¼ 0.560, p < 0.001, Spearman rank
correlation).
4. Discussion
Interleukins are key players in the chronic vascular inflamma-
tion typical of atherosclerosis, with roles that can be intrinsically
pro-atherogenic or anti-atherogenic. In this context, we examined
IL-5 as a potential plasma biomarker for early subclinical carotid
atherosclerosis and change over time in cIMT in a large prospective
European cohort study of high-risk men and womenwhowere free
of clinically overt CVD at enrollment.
The plasma concentration of IL-5 in all participants of this study
was in general low, on average 0.43 (0.27e0.71) pg/mL, a level that
could be accurately measured in this study by increasing the in-
cubation time of the samples with the antibodies on the plate of the
immunoassay. Using other commercially available assays, plasma
IL-5 levels have been reported as low or undetectable, particularly
in samples from subjects in control groups [16,17,21,22]. However,
S€ampi et al. [15] reported IL-5 levels at a much higher level [139
(66e365) pg/mL)], using an assay based on the same principle as
ours, but with antibodies and calibrator from another commercial
source (R&D Systems). For comparison, we set up the assay as
described by S€ampi et al. and re-analyzed a set of 80 random non-
used aliquots of samples from the original cohort but found similar
results as with our assay. The IL-5 concentration in the calibrator
included in the MSD™ IL-5 kit was as reported by the manufac-
turers when analyzed in the assay with the R&D Systems reagents,
which was also true for the reverse test (R&D systems calibrator
analyzed with the MSD™ kit, Supplemental Fig. I shows similar
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Systems materials). It is therefore not appropriate to directly
compare our absolute results with those of S€ampi et al. [15]. In the
absence of an internationally validated calibrator, we should limit
the comparisons to interrelations between variables examined
within each study.
Whereas S€ampi et al. reported low IMT in the bifurcational
section of the carotid artery of subjects with high plasma levels of
IL-5, we observed no significant association between these vari-
ables. Actually we found no association between IL-5 and any
baseline measure of cIMT in the present study. No obvious expla-
nations for this discrepancy are apparent, but differences related to
the study populations (e.g., age difference of 10 years, differences in
risk profile) or even analytes measured by the respective assays
should be considered. In this context, we should note that IL-5 is
considered as a key factor in the regulation of growth, differentia-
tion, recruitment, activation and survival of eosinophils, with
abundant data from in vitro experiments and animal models sug-
gesting that IL-5 inhibition would be an effective approach to treat
eosinophilia [14]. The plasma levels of IL-5 in both male and female
participants of the present study were strongly and positively
correlated with circulating eosinophils across all centers, corrobo-
rating that the protein speciesmeasured in our assaywas indeed IL-
5.
We have observed a south-to-north gradient for IL-5 plasma
concentration in the present study, clustering IL-5 with cardio-
vascular risk factors that also follow a similar pattern. A previous
publication based on the IMPROVE study reported a south-to-north
gradient of cIMT [18]. Consequently, albeit only in men, IL-5 was
positively associated with baseline measures of cIMT, associations
that completely disappeared in multivariable analysis when
adjustment by latitude was made, implying that from south-to-
north there are factors, most likely of genetic, population nature,
with which both IL-5 and cIMT are associated, without being
directly associated with each other. These results suggest that the
plasma IL-5 concentration is not a risk indicator for CVD, contrary
to what was observed in a relatively small study in which IL-5 was
elevated in plasma of patients with unstable angina or myocardial
infarction compared with controls [16], but in line with another
study in which an IL-5 association with (recurrent) cardiovascular
events in univariable analysis disappeared after adjustments [17].
Regarding changes in cIMT during the observation period of 30-
month, the plasma IL-5 concentration showed a consistent and
significant inverse association with changes in IMTmean, (and also
a trend for IMTmax) in the common carotid segment inwomen but
not in men. This sex- and segment-specific finding can be added to
the collection of data suggesting involvement of IL-5 in protection
against atherosclerosis, a notion that has been put forward by early
mouse studies of immunoresponse to oxidized (ox)-LDL [23,24]. It
was observed that immunization of LDLR/ mice with ox-
phospholipid specific-LDL induced expansion of atheroprotective
antibodies from B1-cells that was dependent of the presence of IL-5
because IL-5/ mice did not exhibit this response [23]. Recon-
stitution of LDLR/ mice with bone marrow from IL-5 deficient
mice resulted in significantly more atherosclerosis when compared
with recipients of wild-type bone marrow [23]. Induction of anti-
bodies to ox-LDL dependent of IL-5 has also been reported in the
apolipoprotein E/- mouse model [24]. Moreover, immunization
with ox-LDL in mice caused expansion of specific T-cells of the Th2
subtype that secreted IL-5, which in turn induced expansion of
atheroprotective antibodies [23]. Translating data generated in
experiments with genetically altered mice to the human situation
represents in general a challenge, in particular when involving
features of the immune system in which important differences
exist between mouse and humans [25]. Nevertheless, in line withthe mouse models, a recent publication from the Malm€o Diet and
Cancer (MDC) Study reported the first clinical evidence for a pro-
tective role of Th2 immunity in CVD, high Th2 cell counts observed
to be independently associated with lower IMTmean in the com-
mon carotid segment and with reduced risk of acute myocardial
infarction in women [26]. Although these segment- and sex-
specificities might seem in line with our results, one should keep
inmind that the assumption that Th2 cells are the source of IL-5 has
been challenged both in mice [27] and humans [26]. Of note, in the
MDC Study IL-5 was found not to be associated with baseline cIMT
orwith incident cardiovascular events during a 15 year follow-up of
700 participants, which is consistent with our results, inasmuch IL-
5 in IMPROVE was not associated with baseline cIMT or with inci-
dent coronary events (n¼ 125) during themedian follow-up period
of 21.5 months (later results not shown).
SNPs in the vicinity of the IL-5 gene were identified as being
associated with clinical disease in a gene-centric study of CAD [11],
but as far as we know, replication of this locus has not been re-
ported. Furthermore, we do not know how the IL-5 SNPs in that
study were related to the plasma concentration of IL-5. We cannot
discard the possibility that the association of that locus with CAD is
due to the effect(s) of other gene(s) in the vicinity of IL-5.
The strength of the present study is the uniquely detailed ul-
trasound protocol and the repeated ultrasound measurements,
which for the first time allowed study of IL-5 in relation to change
over time in cIMT, and also its large sample size. However there are
also limitations to be considered, including the fact that carotid IMT
does not solely reflect atherosclerosis although it is a widely used
surrogate marker of subclinical atherosclerosis and predictor of
coronary and cerebrovascular events. Also, multiple test correction
was not applied evenwhen a large number of tests was performed,
which could potentially increase the possibility of spurious find-
ings. However the cIMT variables studied were strongly correlated
with each other or were composite variables of related measure-
ments and therefore provide similar information. Of note, investi-
gation of the effects of latitude (North-to-South gradient over
Europe) was not an objective of the IMPROVE study. In the cross-
sectional analysis of the IMPROVE baseline data a North-to-South
gradient of carotid IMT was observed independent of differences
in vascular risk factors, suggesting involvement of mechanisms of
genetic and/or environmental nature [18]. Thus, latitude in this
context was used as a proxy for center to gain statistical power
(continuous versus nominal scale).
In conclusion, atherosclerosis and cIMT are complex traits to
which many factors contribute. It is plausible that IL-5 is one of
these factors, exerting a protective effect. This effect was clearly
seen in animal models of atherosclerosis because they have
extreme gene defects, with defined trial diets, special experimental
environment and limited immunological challenges. In humans, a
protective effect of IL-5 may be observed depending on the clinical
context, and therefore IL-5 would have limited utility as a classical
biomarker. Whereas IL-5 has been proposed as a potential molec-
ular target to treat allergies, it is difficult to envisage such a scenario
in CAD.
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